Roche halts clinical trial

Swiss pharmaceutical giant Roche has suspended clinical trials of a treatment for rheumatoid arthritis following safety concerns.

This content was published on March 8, 2010 minutes

The joint project with United States biotech group Biogen Idec was developing the Ocrelizumab treatment for the condition.

A review by the Ocrelizumab Rheumatoid Arthritis and Lupus Data and Safety Monitoring Board (DSMB) found the safety risk outweighed benefits observed in the test populations. The review detected an indicator for serious infections, some of which were fatal.

"Patient safety is of the utmost importance in all of our drug development programmes,” said Hal Barron, chief medical officer at Roche, in announcing the trials were suspended.

A detailed analysis of all the data would be conducted and the future of the Ocrelizumab rheumatoid arthritis clinical programme was under evaluation, added Roche. The programme is being implemented in more than 30 countries. and agencies

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Share this story

Change your password

Do you really want to delete your profile?